New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapi...
In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...
Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...
This ADHD Awareness Month, we stand with the ADHD community. Alora Pharmaceuticals, LLC, the largest U.S. manufacturer of methylphenidate medications,...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the la...
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...
Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China wil...
Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...
Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance wit...
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology comp...
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivot...
© 2025 Biopharma Boardroom. All Rights Reserved.
